Efficacy of Rho-Kinase inhibitor in Post-operative Striate Keratopathy

Safety and efficacy of rho-kinase inhibitor for treatment of postoperative striate keratopathy.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/065348

Enrollment

300

Registered

2024-04-08

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H590- Disorders of the eye following cataract surgery

Interventions

Intervention1: Sodium chloride : Topical eyedrops QID for 5 days Control Intervention1: E/D Ripasudil 4%: E/D RIPATEC- Ajanta pharmaceutical Control Intervention2: E/D SODIUM CHLORIDE 5%: E/d SOLIN

Eligibility

Inclusion criteria

Inclusion criteria: a) Striate keratopathy post uneventful cataract surgery [Both SICS & Phacoemulsification ] b) Pre operative healthy clear cornea c) No DMD

Exclusion criteria

Exclusion criteria: a) Pre existing corneal disorder b) DMD c) Aphakia, Vitreous in AC d) Endophthalmitis e) Known case of glaucoma

Design outcomes

Primary

Measure	Time frame
Improvement in corneal clarity with rho kinase inhibitor in striate keratopathy post cataract surgeryTimepoint: Cornea clarity will be checked at post operative day 1 ,day 5, day 10 and day 30	—

Secondary

Measure	Time frame
Decrease in Striate keratopathyTimepoint: 7-15 DAYS POST OPEARTIVE DAYS	—

Countries

India

Contacts

Public ContactDr Keerti Wali

SHRI B M PATIL MEDICAL COLLEGE, HOSPITAL AND RESEARCH CENTER, VIJAYAPURA, KARNATAKA

keertignec14@gmail.com8722289221

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026